238 related articles for article (PubMed ID: 9788400)
21. Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma.
Yoon MS; Chung WK; Ahn SJ; Nam TK; Nah BS; Song JY; Lim SC; Lee JK
Acta Otolaryngol; 2008 May; 128(5):590-6. PubMed ID: 18421617
[TBL] [Abstract][Full Text] [Related]
22. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy--a multicenter randomized trial.
Olmi P; Crispino S; Fallai C; Torri V; Rossi F; Bolner A; Amichetti M; Signor M; Taino R; Squadrelli M; Colombo A; Ardizzoia A; Ponticelli P; Franchin G; Minatel E; Gobitti C; Atzeni G; Gava A; Flann M; Marsoni S
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):78-92. PubMed ID: 12504039
[TBL] [Abstract][Full Text] [Related]
23. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx.
Loong HH; Winquist E; Waldron J; Chen EX; Kim J; Palma D; Read N; Razak AR; Diaz-Padilla I; Chan K; Bayley A; Hossain M; Wang L; Chin S; Siu LL; Hope A
Eur J Cancer; 2014 Sep; 50(13):2263-70. PubMed ID: 24953566
[TBL] [Abstract][Full Text] [Related]
25. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study.
Lefebvre JL; Pointreau Y; Rolland F; Alfonsi M; Baudoux A; Sire C; de Raucourt D; Malard O; Degardin M; Tuchais C; Blot E; Rives M; Reyt E; Tourani JM; Geoffrois L; Peyrade F; Guichard F; Chevalier D; Babin E; Lang P; Janot F; Calais G; Garaud P; Bardet E
J Clin Oncol; 2013 Mar; 31(7):853-9. PubMed ID: 23341517
[TBL] [Abstract][Full Text] [Related]
26. Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: four-year results of a phase I/II study.
Leyvraz S; Pasche P; Bauer J; Bernasconi S; Monnier P
J Clin Oncol; 1994 Sep; 12(9):1876-85. PubMed ID: 8083711
[TBL] [Abstract][Full Text] [Related]
27. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
[TBL] [Abstract][Full Text] [Related]
28. Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil.
Wibault P; Bensmaine MA; de Forni M; Armand JP; Tellez Bernal E; Guillot T; Recondo G; Domenge C; Janot F; Borel C; Luboinski B; Eschwege F; Cvitkovic E
J Clin Oncol; 1996 Apr; 14(4):1192-200. PubMed ID: 8648374
[TBL] [Abstract][Full Text] [Related]
29. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
30. Radiotherapy and concomitant intra-arterial docetaxel combined with systemic 5-fluorouracil and cisplatin for oropharyngeal cancer: a preliminary report--improvement of locoregional control of oropharyngeal cancer.
Oikawa H; Nakamura R; Nakasato T; Nishimura K; Sato H; Ehara S
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):338-42. PubMed ID: 19735860
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of tolerance and efficacy of hyperfractionated radiotherapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in stage III and IV inoperable and/or unresectable head-and-neck squamous cell carcinoma: A-2 protocol.
Abitbol A; Abdel-Wahab M; Lewin A; Troner M; Rodrigues MA; Hamilton-Nelson KL; Markoe A
Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):942-7. PubMed ID: 12095561
[TBL] [Abstract][Full Text] [Related]
32. Role of concomitant chemoradiation in locally advanced head and neck cancers.
Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA
Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361
[TBL] [Abstract][Full Text] [Related]
33. A two-arm multicenter phase II trial of one cycle chemoselection split-dose docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy before two cycles of split TPF followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1).
Inhestern J; Schmalenberg H; Dietz A; Rotter N; Maschmeyer G; Jungehülsing M; Grosse-Thie C; Kuhnt T; Görner M; Sudhoff H; Wittekindt C; Guntinas-Lichius O
Ann Oncol; 2017 Aug; 28(8):1917-1922. PubMed ID: 28498880
[TBL] [Abstract][Full Text] [Related]
34. [Cancers of the base of the tongue and hypopharynx: results of a multicenter randomized trial of chemotherapy prior to locoregional treatment].
Gedouin D; Desprez P; Perron JJ; Fleury F; Leclech G; Miglianico L; Belpomme D; Chenal C
Bull Cancer Radiother; 1996; 83(2):104-7. PubMed ID: 8688215
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of cisplatin, tegafur plus uracil and leucovorin as neoadjuvant chemotherapy in patients with squamous cell carcinoma of the oropharynx and hypopharynx.
Wang HM; Hsueh CT; Wang CS; Chen IH; Liao CT; Tsai MH; Yeh SP; Chang JT
Anticancer Drugs; 2005 Apr; 16(4):447-53. PubMed ID: 15746582
[TBL] [Abstract][Full Text] [Related]
36. Dose-escalated intensity-modulated radiotherapy is feasible and may improve locoregional control and laryngeal preservation in laryngo-hypopharyngeal cancers.
Miah AB; Bhide SA; Guerrero-Urbano MT; Clark C; Bidmead AM; St Rose S; Barbachano Y; A'hern R; Tanay M; Hickey J; Nicol R; Newbold KL; Harrington KJ; Nutting CM
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):539-47. PubMed ID: 21236602
[TBL] [Abstract][Full Text] [Related]
37. Analysis of efficacy and toxicity of chemotherapy with cisplatin, 5-fluorouracil, methotrexate and leucovorin (PFML) and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck.
Katori H; Tsukuda M; Taguchi T
Cancer Chemother Pharmacol; 2007 May; 59(6):789-94. PubMed ID: 17053926
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of cisplatin, 5-fluorouracil and folinic acid using a weekly 24-h infusion schedule for locally advanced head and neck cancer: a pharmacokinetic and clinical survey.
Riva C; Lavieille JP; Schmerber S; Cuisnie O; Reyt E
Int J Oncol; 2000 Sep; 17(3):543-9. PubMed ID: 10938396
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Brockstein BE; Weichselbaum RR
Semin Radiat Oncol; 1999 Apr; 9(2 Suppl 1):70-6. PubMed ID: 10210543
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
